Standard BioTools Inc. reported a 5% revenue increase to $21.1 million in Q1 2026, driven by strong consumables sales despite a 33% drop in instrument revenue. The company reduced its operating loss by 54% and improved adjusted EBITDA loss by 78%, signaling progress toward profitability in 2026. With $524 million in cash and investments, Standard BioTools plans to pursue growth opportunities following the sale of SomaLogic. The company maintains its 2026 revenue forecast of $80-$85 million, focusing on cost savings and strategic capital deployment.
Gold and silver prices increased due to a weaker U.S. dollar and lower U.S. Treasury yields, driven by a drop in oil prices following eased tensions in the Strait of Hormuz. Spot gold rose over 1% to $4,560 and silver reached $78 per ounce. The decli...
GRASS is a decentralized physical infrastructure network (DePIN) focusing on crowdsourcing public web data for AI training. It enables individuals to share unused bandwidth to gather specialized, fresh datasets for AI model builders, who pay for comp...
Grindr's board has rejected a takeover offer of $18 per share, believing it undervalues the company's growth prospects. Despite a slowdown in competitors like Match Group and Bumble, Grindr continues to grow revenue by over 30% year-over-year. The co...
Sei, a blockchain originally built on Cosmos, is considering a shift to an EVM-only platform, prioritizing Ethereum-compatible smart contracts over Cosmos-native CosmWasm. This move aims to leverage Ethereum's broader developer tools, liquidity, and ...
Navios Maritime (NMM) is rated Buy due to its strong earnings, organic growth, and a significant 56% discount to net asset value (NAV). The company operates a diversified fleet of 149 vessels across dry bulk, containerships, and tankers, maintaining ...
